ADRIATIC: A phase III trial of durvalumab 6 tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer

S. Senan, N. Shire, G. Mak, W. Yao, H. Jiang

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)25-25
JournalAnnals of Oncology
Volume30
Publication statusPublished - Apr 2019

Cite this

@article{43c859978f994f9f95edae9b8c7fc212,
title = "ADRIATIC: A phase III trial of durvalumab 6 tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer",
author = "S. Senan and N. Shire and G. Mak and W. Yao and H. Jiang",
year = "2019",
month = "4",
language = "English",
volume = "30",
pages = "25--25",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",

}

ADRIATIC: A phase III trial of durvalumab 6 tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer. / Senan, S.; Shire, N.; Mak, G.; Yao, W.; Jiang, H.

In: Annals of Oncology, Vol. 30, 04.2019, p. 25-25.

Research output: Contribution to journalMeeting AbstractAcademic

TY - JOUR

T1 - ADRIATIC: A phase III trial of durvalumab 6 tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer

AU - Senan, S.

AU - Shire, N.

AU - Mak, G.

AU - Yao, W.

AU - Jiang, H.

PY - 2019/4

Y1 - 2019/4

M3 - Meeting Abstract

VL - 30

SP - 25

EP - 25

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -